Advertisement

Endocrine

, Volume 56, Issue 3, pp 633–638 | Cite as

Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study

  • Davide CampanaEmail author
  • Davide Ravizza
  • Piero Ferolla
  • Antongiulio Faggiano
  • Franco Grimaldi
  • Manuela Albertelli
  • Claudio Ricci
  • Donatella Santini
  • Nicole Brighi
  • Nicola Fazio
  • Annamaria Colao
  • Diego Ferone
  • Paola Tomassetti
Original Article

Abstract

The aim of this retrospective study was to evaluate the presence of risk factors for a type 1 gastric neuroendocrine neoplasia in a large cohort of patients with chronic atrophic gastritis. The study design consisted of an Italian multicentre, retrospective analysis. The study included all consecutive patients with chronic atrophic gastritis with or without type 1 gastric neuroendocrine neoplasias followed at the participating centres. Two hundred and twenty-nine patients with chronic atrophic gastritis were enroled at the participating centres. A total of 207 patients (154 female, 53 males, median age: 56.0 years) were included in the final analysis. One hundred and twenty-six patients had chronic atrophic gastritis without a gastric neuroendocrine neoplasia and 81 had a chronic atrophic gastritis with type 1 gastric neuroendocrine neoplasia. The median Chromogranin A level, evaluated in 141 patients, was 52.0 U/L. At upper gastrointestinal endoscopy, atrophy of the gastric mucosa was mild/moderate in 137 patients and severe in 68. Intestinal metaplasia of the corpus was present in 168 patients. At histological examination, 81 patients had a gastric neuroendocrine neoplasia (42 patients had a NET G1 and 33 a NET G2). The median Ki67 index was 2.0 %. At univariate and multivariate analysis, the risk factors for a gastric neuroendocrine neoplasia were: male gender, chromogranin A greater than 61 U/L, presence of intestinal metaplasia and age equal to or greater than 59 years. Chromogranin A greater than 61 U/L, the presence of intestinal metaplasia and male gender were independent risk factors for a type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis.

Keywords

Neuroendocrine tumours Chronic atrophic gastritis Gastric carcinoid Gastrin Chromogranin A 

Notes

Acknowledgments

All authors approved the final version of the article, including the authorship list.

Compliance with ethical standards

Conflict of interest

Dr. Antongiulio Faggiano has received research grants from NOVARTIS Farma s.p.a. and IPSEN PHARMA. The other authors declare that they have no conflict of interest.

References

  1. 1.
    M. Rugge, P. Correa, M.F. Dixon, R. Fiocca, T. Hattori, J. Lechago, G. Leandro, A.B. Price, P. Sipponen, E. Solcia, H. Watanabe, R.M. Genta, Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment. Pharmacol. Ther. 16, 1249–1259 (2002)CrossRefPubMedGoogle Scholar
  2. 2.
    M.D. Burkitt, D.M. Pritchard, Review article: pathogenesis and management of gastric carcinoid tumours. Aliment. Pharmacol. Ther. 24, 1305–1320 (2006)CrossRefPubMedGoogle Scholar
  3. 3.
    G. Rindi, O. Luinetti, M. Cornaggia, C. Capella, E. Solcia, Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 104, 994–1006 (1993)CrossRefPubMedGoogle Scholar
  4. 4.
    H.L. Waldum, A.K. Sandvik, J.R. Idle, Gastrin is the most important factor in ECL tumorigenesis. Gastroenterology 114, 1113–1115 (1998)CrossRefPubMedGoogle Scholar
  5. 5.
    K. Borch, B. Ahren, H. Ahlman, S. Falkmer, G. Granerus, L. Grimelius, Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg. 242, 64–73 (2005)CrossRefGoogle Scholar
  6. 6.
    K. Borch, H. Renvall, G. Liedberg, Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology 88, 638–648 (1985)CrossRefPubMedGoogle Scholar
  7. 7.
    G. Rindi, C. Azzoni, S. La Rosa, C. Klersy, D. Paolotti, S. Rappel, M. Stolte, C. Capella, C. Bordi, E. Solcia, ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 116, 532–542 (1999)CrossRefPubMedGoogle Scholar
  8. 8.
    O. Hosokawa, Y. Kaizaki, M. Hattori, K. Douden, H. Hayashi, M. Morishita, K. Ohta, Long-term follow up of patients with multiple gastric carcinoids associated with type A gastritis. Gastric Cancer 8, 42–46 (2005)CrossRefPubMedGoogle Scholar
  9. 9.
    M.F. Dixon, R.M. Genta, J.H. Yardley, P. Correa, Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am. J. Surg. Pathol. 20, 1161–1181 (1996)CrossRefPubMedGoogle Scholar
  10. 10.
    F.T. Bosman, F. Carneiro, R.H. Hruban, N.D. Theise. WHO Classification of Tumors of the Digestive System. 4th edn. IARC, Lyon, (2010)Google Scholar
  11. 11.
    G. Rindi, G. Kloppel, H. Alhman, M. Caplin, A. Couvelard, W.W. de Herder, B. Erikssson, A. Falchetti, M. Falconi, P. Komminoth, M. Korner, J.M. Lopes, A.M. McNicol, O. Nilsson, A. Perren, A. Scarpa, J.Y. Scoazec, B. Wiedenmann, TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 449, 395–401 (2006)CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    D. Campana, F. Nori, L. Piscitelli, A.M. Morselli-Labate, R. Pezzilli, R. Corinaldesi, P. Tomassetti, Chromogranin A: is it a useful marker of neuroendocrine tumors? J. Clin. Oncol. 25, 1967–1973 (2007)CrossRefPubMedGoogle Scholar
  13. 13.
    M.C. Zatelli, M. Torta, A. Leon, M.R. Ambrosio, M. Gion, P. Tomassetti, F. De Brau, G. Delle Fave, L. Dogliotti, E.C. degli Uberti, Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr. Relat. Cancer 14, 473–482 (2007)CrossRefPubMedGoogle Scholar
  14. 14.
    I.M. Modlin, B.I. Gustafsson, S.F. Moss, M. Pavel, A.V. Tsolakis, M. Kidd, Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease. Ann. Surg. Oncol. 17, 2427–2443 (2010)CrossRefPubMedGoogle Scholar
  15. 15.
    K. Borch, M. Stridsberg, P. Burman, J.F. Rehfeld, Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand. J. Gastroenterol. 32, 198–202 (1997)CrossRefPubMedGoogle Scholar
  16. 16.
    M. Peracchi, C. Gebbia, G. Basilisco, M. Quatrini, C. Tarantino, C. Vescarelli, S. Massironi, D. Conte, : Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur. J. Endocrinol. 152, 443–448 (2005)CrossRefPubMedGoogle Scholar
  17. 17.
    L. Vannella, A. Sbrozzi-Vanni, E. Lahner, C. Bordi, E. Pilozzi, V.D. Corleto, J.F. Osborn, G. Delle Fave, B. Annibale, Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Aliment. Pharmacol. Ther. 33, 1361–1369 (2011)CrossRefPubMedGoogle Scholar
  18. 18.
    A.C. de Vries, E.J. Kuipers, Epidemiology of premalignant gastric lesions: implications for the development of screening and surveillance strategies. Helicobacter 12(Suppl 2), 22–31 (2007)CrossRefPubMedGoogle Scholar
  19. 19.
    H. Ohata, S. Kitauchi, N. Yoshimura, K. Mugitani, M. Iwane, H. Nakamura, A. Yoshikawa, K. Yanaoka, K. Arii, H. Tamai, Y. Shimizu, T. Takeshita, O. Mohara, M. Ichinose, Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int. J. Cancer 109, 138–143 (2004)CrossRefPubMedGoogle Scholar
  20. 20.
    M. Tatsuta, H. Iishi, A. Nakaizumi, S. Okuda, H. Taniguchi, T. Hiyama, H. Tsukuma, A. Oshima, Fundal atrophic gastritis as a risk factor for gastric cancer. Int. J. Cancer 53, 70–74 (1993)CrossRefPubMedGoogle Scholar
  21. 21.
    S. Shichijo, Y. Hirata, K. Sakitani, S. Yamamoto, T. Serizawa, R. Niikura, H. Watabe, S. Yoshida, A. Yamada, Y. Yamaji, T. Ushiku, M. Fukayama, K. Koike, Distribution of intestinal metaplasia as a predictor of gastric cancer development. J. Gastroenterol. Hepatol 30, 1260–1264 (2015)CrossRefPubMedGoogle Scholar
  22. 22.
    W.K. Leung, J.J. Sung, Review article: intestinal metaplasia and gastric carcinogenesis. Aliment. Pharmacol. Ther. 16, 1209–1216 (2002)CrossRefPubMedGoogle Scholar
  23. 23.
    Y.H. Park, N. Kim, Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer. J. Cancer Prev. 20, 25–40 (2015)CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    A. Nicolaou, D. Thomas, K.I. Alexandraki, S. Sougioultzis, A.V. Tsolakis, G. Kaltsas, Predictive value of gastrin levels for the diagnosis of gastric enterochromaffin-like cell hyperplasia in patients with Hashimoto’s thyroiditis. Neuroendocrinology 99, 118–122 (2014)CrossRefPubMedGoogle Scholar
  25. 25.
    A. Vanoli, S. La Rosa, O. Luinetti, C. Klersy, R. Manca, C. Alvisi, S. Rossi, E. Trespi, A. Zangrandi, F. Sessa, C. Capella, E. Solcia, Histologic changes in type A chronic atrophic gastritis indicating increased risk of neuroendocrine tumor development: the predictive role of dysplastic and severely hyperplastic enterochromaffin-like cell lesions. Hum. Pathol 44, 1827–1837 (2013)CrossRefPubMedGoogle Scholar
  26. 26.
    K.I. Alexandraki, A. Nikolaou, D. Thomas, V. Syriou, P. Korkolopoulou, S. Sougioultzis, G. Kaltsas, Are patients with autoimmune thyroid disease and autoimmune gastritis at risk of gastric neuroendocrine neoplasms type 1? Clin. Endocrinol. (Oxf.) 80, 685–690 (2014)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Davide Campana
    • 1
    Email author
  • Davide Ravizza
    • 2
  • Piero Ferolla
    • 3
  • Antongiulio Faggiano
    • 4
  • Franco Grimaldi
    • 5
  • Manuela Albertelli
    • 6
    • 7
  • Claudio Ricci
    • 1
  • Donatella Santini
    • 8
  • Nicole Brighi
    • 9
  • Nicola Fazio
    • 2
  • Annamaria Colao
    • 4
  • Diego Ferone
    • 6
    • 7
  • Paola Tomassetti
    • 1
  1. 1.Department of Medical and Surgical SciencesS.Orsola-Malpighi University HospitalBolognaItaly
  2. 2.Division of Endoscopy and Unit of Gastrointestinal and Neuroendocrine TumoursEuropean Institute of OncologyMilanItaly
  3. 3.Department of Medical OncologyMultidisciplinary NET Centre, Umbria Regional Cancer NetworkUmbriaItaly
  4. 4.Division of Endocrinology, Department of Clinical Medicine and Surgery“Federico II” University of NaplesNaplesItaly
  5. 5.Endocrinology and Metabolism UnitUniversity Hospital S. Maria della MisericordiaUdineItaly
  6. 6.Endocrinology, Department of Internal Medicine and Medical Specialties (DiMI) and Centre of Excellence for Biomedical Research (CEBR)University of GenovaGenoaItaly
  7. 7.IRCCS-AOU San Martino-ISTGenovaItaly
  8. 8.Dipartimento della medicina diagnostica e della prevenzioneS.Orsola-Malpighi University HospitalBolognaItaly
  9. 9.Department of ExperimentalDiagnostic and Specialty medicine S.Orsola-Malpighi University HospitalBolognaItaly

Personalised recommendations